CA3301344A1 - Cb1 receptor antigen-binding proteins and uses thereof - Google Patents

Cb1 receptor antigen-binding proteins and uses thereof

Info

Publication number
CA3301344A1
CA3301344A1 CA3301344A CA3301344A CA3301344A1 CA 3301344 A1 CA3301344 A1 CA 3301344A1 CA 3301344 A CA3301344 A CA 3301344A CA 3301344 A CA3301344 A CA 3301344A CA 3301344 A1 CA3301344 A1 CA 3301344A1
Authority
CA
Canada
Prior art keywords
binding proteins
receptor antigen
antigen
receptor
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3301344A
Other languages
English (en)
Inventor
Peter Coward
Jr. MOORE Steven A.
Shi-Yuan Meng
Mei-Mei Tsai
Chadwick Terence King
Aaron Avraham NAZARIAN
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3301344A1 publication Critical patent/CA3301344A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3301344A 2013-06-26 2014-06-25 Cb1 receptor antigen-binding proteins and uses thereof Pending CA3301344A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361839458P 2013-06-26 2013-06-26
US61/839,458 2013-06-26
CA2915386A CA2915386A1 (en) 2013-06-26 2014-06-25 Cb1 receptor antigen-binding proteins and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2915386A Division CA2915386A1 (en) 2013-06-26 2014-06-25 Cb1 receptor antigen-binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
CA3301344A1 true CA3301344A1 (en) 2026-03-02

Family

ID=51177217

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3301344A Pending CA3301344A1 (en) 2013-06-26 2014-06-25 Cb1 receptor antigen-binding proteins and uses thereof
CA2915386A Pending CA2915386A1 (en) 2013-06-26 2014-06-25 Cb1 receptor antigen-binding proteins and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2915386A Pending CA2915386A1 (en) 2013-06-26 2014-06-25 Cb1 receptor antigen-binding proteins and uses thereof

Country Status (6)

Country Link
US (1) US10227406B2 (https=)
EP (1) EP3013860B1 (https=)
JP (6) JP6562912B2 (https=)
AU (1) AU2014302410B2 (https=)
CA (2) CA3301344A1 (https=)
WO (1) WO2014210205A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39708A (fr) 2014-03-27 2021-03-31 Bird Rock Bio Inc Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain
BR112018006633A2 (en) * 2015-09-30 2018-10-23 Bird Rock Bio, Inc. antibodies that bind to human cannabinoid receptor 1 (cb1)
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
US12269898B2 (en) 2017-10-04 2025-04-08 Amgen Inc. Transthyretin immunoglobulin fusions
CA3098416A1 (en) 2018-04-30 2019-11-07 Takeda Pharmaceutical Company Limited Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
JP7430624B2 (ja) 2020-11-27 2024-02-13 株式会社ブリヂストン タイヤ組立体
WO2022164239A1 (ko) 2021-01-28 2022-08-04 주식회사 파미노젠 피라졸-카르복스아미드 유도체 화합물 및 이의 용도
JPWO2023234406A1 (https=) * 2022-06-03 2023-12-07
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023232A2 (en) 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
US7655685B2 (en) 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2012513469A (ja) * 2008-12-23 2012-06-14 シェーリング コーポレイション ピリミジン誘導体及びその使用法
WO2011072336A1 (en) * 2009-12-18 2011-06-23 The University Of Sydney Antiviral agents

Also Published As

Publication number Publication date
AU2014302410A1 (en) 2015-12-24
JP2020196763A (ja) 2020-12-10
JP2025163008A (ja) 2025-10-28
EP3013860A1 (en) 2016-05-04
AU2014302410B2 (en) 2019-06-13
JP2018201516A (ja) 2018-12-27
US20160145333A1 (en) 2016-05-26
JP2016523910A (ja) 2016-08-12
HK1224311A1 (en) 2017-08-18
JP2022037087A (ja) 2022-03-08
CA2915386A1 (en) 2014-12-31
WO2014210205A1 (en) 2014-12-31
JP6562912B2 (ja) 2019-08-21
JP7018104B2 (ja) 2022-02-09
EP3013860B1 (en) 2018-12-12
JP2023171760A (ja) 2023-12-05
US10227406B2 (en) 2019-03-12

Similar Documents

Publication Publication Date Title
IL261743B (en) and their uses 33–il antibodies against
IL261547B (en) Antibodies against pesidine and their uses
EP3003390A4 (en) Anti-c10orf54 antibodies and uses thereof
EP3089994A4 (en) Fabs-in-tandem immunoglobulin and uses thereof
IL245040B (en) Antibodies against pdgfr-beta and their uses
IL243974A0 (en) Antibodies against -prlr and uses
EP3026062A4 (en) Anti-pd-1 antibody and use thereof
IL240443A0 (en) Antibodies against tnf-a with a high level of galactosylation and their uses
EP3019531A4 (en) Immunoglobulin fusion proteins and compositions thereof
SG10201709715RA (en) Anti-b7-h5 antibodies and their uses
EP3083698A4 (en) Monoclonal anti-tk1 antibodies
EP3066470A4 (en) Humanized anti-ceacam5 antibody and uses thereof
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
EP3024850A4 (en) Anti-galectin-1 monoclonal antibodies and fragments thereof
CA3301344A1 (en) Cb1 receptor antigen-binding proteins and uses thereof
EP3065774A4 (en) Anti-ccl17 antibodies
EP3209686A4 (en) Monoclonal anti-gpc-1 antibodies and uses thereof
SG11201602760YA (en) Monoclonal olfml-3 antibodies and uses thereof
EP3066122A4 (en) Pre-haptoglobin-2 monoclonal antibodies and uses thereof
AU2013901830A0 (en) Antibodies and uses thereof
HK1227906A1 (en) Fabs-in-tandem immunoglobulin and uses thereof
AU2013901568A0 (en) Anti-12r antibodies and il23r antibodies and uses thereof
AU2013901925A0 (en) G protein coupled receptor libraries
AU2013901329A0 (en) G protein coupled receptor libraries
AU2013901678A0 (en) Antigenic polypeptides and antibodies thereto

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20260210

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260210

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260210

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260217

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260217

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260217

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20260227

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20260227

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20260302

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260317

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20260317